Jasbir Seehra - 24 Feb 2026 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)

Role
CHIEF EXECUTIVE OFFICER, Director
Signature
/s/ Jasbir Seehra
Issuer symbol
KROS
Transactions as of
24 Feb 2026
Net transactions value
$0
Form type
4
Filing time
26 Feb 2026, 16:15:24 UTC
Previous filing
20 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Seehra Jasbir CHIEF EXECUTIVE OFFICER, Director C/O KEROS THERAPEUTICS, INC., 1050 WALTHAM STREET, SUITE 302, LEXINGTON /s/ Jasbir Seehra 26 Feb 2026 0001732369

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KROS Employee Stock Option (Right to Buy) Award $0 +217,000 $0.000000 217,000 24 Feb 2026 Common Stock 217,000 $15.52 Direct F1
transaction KROS Employee Stock Option (right to buy) Award $0 +100,000 $0.000000 100,000 24 Feb 2026 Common Stock 100,000 $15.52 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One-fourth (1/4th) of the shares subject to the option shall vest on February 24, 2027, and the remaining shares subject to the option shall vest in twelve substantially equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.
F2 The shares subject to the option shall vest in one-fourth (1/4th) increments upon the closing price of the Issuer's common stock equaling or exceeding 125%, 150%, 175% and 200%, respectively, of the exercise price for 30 calendar days between February 24, 2026 and February 24, 2031, subject to the Reporting Person's continuous service through each vesting date.